# Contents

**Part I  Introduction**

**Healthcare Provisions in an Aging Society: U.S. Perspective.**  
Ajoy C. Karikkineth  
3

**Healthcare Provision in an Aging Society—The European Perspective.**  
Peter Crome and Joanna Pleming  
23

**Healthcare Provisions in the Aging Society: Japanese Perspectives.**  
Naoko Muramatsu  
45

**Part II  The Patient(s)**

**Old, Very Old and Frail.**  
Jean-Pierre Baeyens  
61

**Age and the Process of Aging.**  
Paul A.F. Jansen  
67

**Comprehensive Geriatric Assessment.**  
Jacob Blumenthal and Steven R. Gambert  
87

**Patients’ Clinical Characteristics, Disease Experience, and Perception.**  
Sven Stegemann  
103

**Part III  Clinical Development of Drug Products for Older Adults**

**Ethical Considerations in Performing Clinical Trials in and for Older People.**  
Florian von Raison and Laurence Hugonot-Diener on behalf of the Geriatric Medicine Working Party (GMWP), European Forum of Good Clinical Practice (EFGCP)  
117
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Reported Outcomes in Clinical Trials and Practice with Older Patients</td>
<td>129</td>
</tr>
<tr>
<td>Sven Stegemann</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetic and Pharmacodynamic Considerations in Elderly Population</td>
<td>139</td>
</tr>
<tr>
<td>Jatinder Kaur Mukker, Ravi Shankar Prasad Singh and Hartmut Derendorf</td>
<td></td>
</tr>
<tr>
<td>The Expectation to Treatment Model: A Framework for Adherence and Effectiveness</td>
<td>153</td>
</tr>
<tr>
<td>Sven Stegemann</td>
<td></td>
</tr>
<tr>
<td>Pharmacoepidemiology and Pharmacovigilance for Safety and Efficacy in Older People</td>
<td>171</td>
</tr>
<tr>
<td>Sarah N. Hilmer and Danijela Gnjidic</td>
<td></td>
</tr>
<tr>
<td>Part IV Product Development for Older Adults</td>
<td></td>
</tr>
<tr>
<td>Defining Patient Centric Drug Product Design and Its Impact on Improving Safety and Effectiveness</td>
<td>191</td>
</tr>
<tr>
<td>Sven Stegemann</td>
<td></td>
</tr>
<tr>
<td>Dosing Considerations in Older Adults</td>
<td>217</td>
</tr>
<tr>
<td>Gregory J. Hughes and Judith L. Beizer</td>
<td></td>
</tr>
<tr>
<td>Oral Drug Product Use in the Elderly Patient Population</td>
<td>225</td>
</tr>
<tr>
<td>Robert L. Ternik</td>
<td></td>
</tr>
<tr>
<td>Drug Product Development for Older Adults—Multiparticulate Formulations</td>
<td>247</td>
</tr>
<tr>
<td>Norbert Pöllinger</td>
<td></td>
</tr>
<tr>
<td>Considerations for Topical and Transdermal Drug Delivery in Older Adults</td>
<td>279</td>
</tr>
<tr>
<td>Sven Stegemann</td>
<td></td>
</tr>
<tr>
<td>Parenteral Drug Delivery for Older Patients</td>
<td>291</td>
</tr>
<tr>
<td>Sagarika Bose</td>
<td></td>
</tr>
<tr>
<td>Inhalation and Nasal Formulations</td>
<td>331</td>
</tr>
<tr>
<td>Jolyon Mitchell</td>
<td></td>
</tr>
<tr>
<td>Ophthalmic Drug Development and the Elderly</td>
<td>383</td>
</tr>
<tr>
<td>Patrick Hughes and Sesha Neervannan</td>
<td></td>
</tr>
<tr>
<td>Developing Drug Administration Devices for Geriatric Use</td>
<td>403</td>
</tr>
<tr>
<td>Tom Sam</td>
<td></td>
</tr>
<tr>
<td>Manufacturing Platforms for Patient-Centric Drug Products</td>
<td>447</td>
</tr>
<tr>
<td>Mark W. Wilson</td>
<td></td>
</tr>
</tbody>
</table>
Novel Manufacturing Technologies for the Production of Patient-Centric Drug Products ................................................ 485
Mark W. Wilson, Luigi Martini and Allan Clarke

Part V Drug Therapy in Older Adults

Prescribing to Older Adults .................................................. 519
Sunny A. Linnebur

Multimorbidity and Polypharmacy .......................................... 549
Jennifer G. Naples and Emily R. Hajjar

Vaccination in Older Adults .................................................... 563
Andreas H. Leischker

Medication Reviews in Older Adults ....................................... 577
Emily P. Peron and Kelechi C. Ogbonna

The Personalization of Drug Therapy for Elderly Patients .......... 589
Jan F. Schlender, Adam G. Golden, Tanay S. Samant,
Chakradhar V. Lagishetty and Stephan Schmidt

Importance of Clinical Nutrition in Therapy to Older Adults ......... 613
Ruediger Thiesemann

Part VI Management of Drug Therapy in Older Adults

Managing Drug Therapy of Older Patients in Primary
and Secondary Care ............................................................ 629
Gabriel Ariza, Marta Martínez-Reig and Pedro Abizanda

Medication Adherence and Monitoring .................................... 659
Hubert Ebner and Günter Schreier

Medication Compounding in the Provision of Drug Therapy ........ 675
Linda F. McElhiney

Geriatric Pharmacotherapy: Optimisation Through Integrated
Approach in the Hospital Setting ............................................ 683
Mirko Petrovic, Annemie Somers and Graziano Onder

Part VII Regulatory Guidance on Geriatric Medicines

European Medicines Agency (EMA): Regulatory Perspectives
on Geriatric Medicines ........................................................ 701
Francesca Cerreta and David Bowen

Views on the Therapeutic Needs of Older Adults ....................... 719
S.W. Johnny Lau and Raman K. Baweja
# Part VIII  Concluding Remarks

**Future Perspectives in Drug Therapy of Older Adults.** 737  
Amanda Lavan, Paul Gallagher and Denis O’Mahony

**Opportunities in Drug Product Development in an Aging Population** 759  
Sven Stegemann

**Erratum to: European Medicines Agency (EMA): Regulatory Perspectives on Geriatric Medicines** E1  
Francesca Cerretta and David Bowen

**Index** 769
Developing Drug Products in an Aging Society
From Concept to Prescribing
Stegemann, S. (Ed.)
2016, XVIII, 771 p. 96 illus., 85 illus. in color., Hardcover
ISBN: 978-3-319-43097-3

http://www.springer.com/978-3-319-43097-3